
Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.
Drs Gutiérrez Junquera and Tzivinikos discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes.

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.
Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.

Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.